ArticleAIDS research and human retroviruses2014
Identification of a novel HIV-1 circulating recombinant form (CRF62_BC) in western Yunnan of China.
Article in AIDS research and human retroviruses, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 31 citations in OpenAlex.
- HIV-1 genetic diversity a challenge for AIDS vaccine development: a retrospective bibliometric analysis.Human vaccines & immunotherapeutics · 2022Article
- Identification of a New HIV-1 Circulating Recombinant Form CRF112_01B Strain in Baoding City, Hebei Province, China.Current HIV research · 2022Article
- Using molecular network analysis to explore the characteristics of HIV-1 transmission in a China-Myanmar border area.PloS one · 2022Article
- Identification of a New HIV-1 BC Intersubtype Circulating Recombinant Form (CRF108_BC) in Spain.Viruses · 2021Article
- Spatial clusters of HIV-1 genotypes in a recently infected population in Yunnan, China.BMC infectious diseases · 2019Article
- The changing HIV-1 genetic characteristics and transmitted drug resistance among recently infected population in Yunnan, China.Epidemiology and infection · 2018Article
- Article
- HIV-1 molecular epidemiology among newly diagnosed HIV-1 individuals in Hebei, a low HIV prevalence province in China.PloS one · 2017Article
- Article
- The Genomic Signature of Population Reconnection Following Isolation: From Theory to HIV.G3 (Bethesda, Md.) · 2015Article
- HIV Epidemic in Asia: Implications for HIV Vaccine and Other Prevention Trials.AIDS research and human retroviruses · 2015Review
- Article
- Development of an HIV-1 Subtype Panel in China: Isolation and Characterization of 30 HIV-1 Primary Strains Circulating in China.PloS one · 2015Article
- Evolving molecular epidemiological profile of human immunodeficiency virus 1 in the southwest border of China.PloS one · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We report here a novel HIV-1 circulating recombinant form (CRF62_BC) that was isolated from three epidemiologically unlinked individuals [one from an injecting drug user (IDU); two from heterosexuals] in Dehong prefecture of western Yunnan province. CRF62_BC harbored two subtype B segments in the pol and vpu-env regions in a subtype C backbone. Subregion tree analysis demonstrated that subtype B regions originated from a Thai-B (subtype B') lineage and the subtype C region was from an India C lineage. CRF62_BC is the fourth CRF composed of subtypes B' and C known to date after CRF07_BC, CRF08_BC, and CRF57_BC, which were originally found among IDUs in China. The emergence of CRF62_BC may indicate the continual generation of new recombinant strains in various high-risk populations in western Yunnan. This may complicate the development of effective vaccines to limit the HIV-1 epidemic and increase the difficulty of AIDS prevention and control in China.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.